Anzeige
❌
Mehr »
Samstag, 10.01.2026 - Börsentäglich über 12.000 News
Fundamental stark, Kurs zu niedrig - Chance beim Krebs-Impfstoff-Pionier!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
09.01.26 | 14:40
32,220 Euro
-0,37 % -0,120
Branche
Biotechnologie
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
32,32032,68009.01.
32,34032,66009.01.

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis286AFX NewsSTOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (publ) (SOBI.ST) or Sobi announced topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven...
► Artikel lesen
MiSwedish Orphan Biovitrum AB: Sobi to advance Gamifant (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data317PR NewswireSTOCKHOLM, Jan. 7, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven...
► Artikel lesen
18.12.25Swedish Orphan Biovitrum AB: Save the Date: Sobi to host a Capital Markets Day on 18 February 2026276PR NewswireSTOCKHOLM, Dec. 18, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
15.12.25Sobi To Acquire Arthrosi For Up To $1.5 Billion, Adding Phase 3 Gout Asset AR8827pulse2.com
15.12.25Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics2MedCity News
15.12.25Sobi to acquire Arthrosi Therapeutics for $950 million upfront3Investing.com
15.12.25SOBI Agrees to Acquire Arthrosi Therapeutics1Contract Pharma
15.12.25Sobi pays $950M upfront to snap up phase 3 gout specialist Arthrosi Therapeutics1FierceBiotech
15.12.25Sobi to Acquire Arthrosi Therapeutics, for USD 950M1FinSMEs
15.12.25Sobi pays $1.5bn for Arthrosi to grow in gout-pharmaphorum
15.12.25Sobi buys Arthrosi to expand gout treatment pipeline1Pharmaceutical Technology
15.12.25Sobi To Acquire Arthrosi Therapeutics297AFX NewsBRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech...
► Artikel lesen
15.12.25Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.371PR NewswireSTOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which...
► Artikel lesen
13.12.25Sobi to acquire Arthrosi Therapeutics for $950 million4Investing.com
13.12.25Swedish Orphan Biovitrum AB: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout2.906PR NewswireExpands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM...
► Artikel lesen
12.12.25Sobi Announces CHMP's Positive Opinion For Aspaveli353AFX NewsBRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sobi (SOBI.ST) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending...
► Artikel lesen
12.12.25Swedish Orphan Biovitrum AB: Sobi Receives Positive CHMP Opinion for Aspaveli (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN878PR NewswireApproximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and...
► Artikel lesen
05.12.25Swedish Orphan Biovitrum AB: Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025523PR NewswireSTOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 - 9 December...
► Artikel lesen
04.12.25Swedish Orphan Biovitrum AB: The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN542PR NewswireRobust and clinically meaningful benefits observed across all three key markers of disease - 68% reduction in proteinuria, stabilisation of kidney function, and substantial clearance of C3...
► Artikel lesen
08.11.25Swedish Orphan Biovitrum AB: Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions638PR NewswireSTOCKHOLM, Nov. 8, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies...
► Artikel lesen
1 2 3 4 5 Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1